Results 1 to 10 of about 546 (157)
Antibiotics, 2019 This meta-analysis aims to assess the efficacy and safety of tedizolid, compared to linezolid, in the treatment of acute bacterial skin and skin structure infection (ABSSSI). PubMed, Web of Science, EBSCO (Elton B.
Shao-Huan Lan +2 more
exaly +4 more sources
Pharmacokinetics and Pharmacodynamics of Tedizolid [PDF]
Clinical Pharmacokinetics, 2022 Tedizolid is an oxazolidinone antibiotic with high potency against Gram-positive bacteria and currently prescribed in bacterial skin and skin-structure infections. The aim of the review was to summarize and critically review the key pharmacokinetic and pharmacodynamic aspects of tedizolid.
Khalid Iqbal +2 more
openaire +3 more sources
Thrombocytopenia with Tedizolid and Linezolid [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Several studies have suggested the risk of thrombocytopenia with tedizolid, a second-in-class oxazolidinone antibiotic (approved June 2014), is less than that observed with linezolid (first-in-class oxazolidinone). Using data from the Food and Drug Administration adverse event reporting system (July 2014 through December 2016), we ...
Lee, Erica Yookyung, Caffrey, R
openaire +5 more sources
Tedizolid Phosphate: a Next-Generation Oxazolidinone [PDF]
Infectious Diseases and Therapy, 2015 Treatment of multidrug-resistant Gram-positive infections continues to challenge clinicians as the emergence of new resistance mechanisms outpaces introduction of novel antimicrobial agents. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus
Jeffrey M Rybak
exaly +3 more sources
Single‐ and Multiple‐Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid [PDF]
Pharmacotherapy, 2014 Objectives Tedizolid phosphate is a novel antibacterial under investigation for the treatment of gram‐positive infections. This study was conducted to assess the pharmacokinetics, safety, and tolerability of intravenous tedizolid phosphate as well as the oral bioavailability of tedizolid phosphate.
Shawn Flanagan, Edward Fang
exaly +3 more sources
In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
Infection and Drug Resistance, 2022 Huiyun Zhang,1 Wenya Hua,1 Siran Lin,1 Yu Zhang,1 Xinchang Chen,1 Shiyong Wang,1 Jiazhen Chen,1 Wenhong Zhang1– 3 1Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center
Zhang H +7 more
doaj +3 more sources
Tedizolid for the Management of Human Infections: In Vitro Characteristics [PDF]
Clinical Infectious Diseases, 2014 The emerging antibiotic resistance of Gram-positive pathogens represents a significant challenge to the management of human infections. The novel oxazolidinone tedizolid demonstrates antimicrobial activity across a broad range of Gram-positive pathogens and greater potency than linezolid against wild-type and drug-resistant pathogens, including ...
Gary E Zurenko, Karen Joy Shaw
exaly +3 more sources
Study on the Efficacy and Safety of Tedizolid in Japanese Patients
AntibioticsBackground/Objective: Tedizolid (TZD), an oxazolidinone, causes fewer adverse events than linezolid (LZD). However, studies on the long-term efficacy and safety of TZD, particularly in patients with hematological malignancies (HMs), remain limited.
Kazuhiro Ishikawa +2 more
doaj +3 more sources
Hospital Pharmacy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J, Cada +2 more
openaire +2 more sources
Journal of Pharmaceutical Health Care and Sciences, 2023 Background Tedizolid is an oxazolidinone anti-MRSA drug with included in the National Health Insurance Drug Price List in 2018. The effect of hemodialysis on tedizolid phosphate concentrations has been reported; pre-dialysis concentrations decreased by ...
Satoshi Yoshikawa +3 more
doaj +1 more source